Insights into the Role of Matrix Metalloproteinases in Precancerous Conditions and in Colorectal Cancer

Colorectal cancer (CRC) is the third and second cancer for incidence and mortality worldwide, respectively, and is becoming prevalent in developing countries. Most CRCs derive from polyps, especially adenomatous polyps, which can gradually transform into CRC. The family of Matrix Metalloproteinases (MMPs) plays a critical role in the initiation and progression of CRC. Prominent MMPs, including MMP-1, MMP-2, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13, MMP-14, and MMP-21, have been detected in CRC patients, and the expression of most of them correlates with a poor prognosis. Moreover, many studies have explored the inhibition of MMPs and targeted therapy for CRC, but there is not enough information about the role of MMPs in polyp malignancy. In this review, we discuss the role of MMPs in colorectal cancer and its pathogenesis

Nonsteroidal Anti-Inflammatory Drugs Reduce Second Cancer Risk in Patients With Breast Cancer: A Nationwide Population-Based Propensity Score-Matched Cohort Study in Taiwan

Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce mortality in patients with cancer, especially breast cancer, but their influence on second cancer risk is uncertain. This study aimed to examine whether NSAID use is associated with second cancer risk in patients with breast cancer. This population-based propensity score-matched cohort study using Taiwan’s National Health Insurance Research Database enrolled patients with newly diagnosed breast cancer (n = 7356) with and without (n = 1839) NSAID therapy from 2000 to 2009. They were followed up until the diagnosis of second cancer, death, or end of 2011. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHR). The NSAID cohort had a lower incidence rate of second cancer than the non-NSAID cohort (5.57 vs. 9.19 per 1,000 person-years), with an aHR of 0.63 (95% confidence interval (CI) 0.46–0.87). When compared with the non-NSAID cohort, the second cancer incidence was lower in patients taking non-cyclooxygenase 2 inhibitors (aHR 0.67, 95% CI 0.47–0.94) and in those receiving multiple NSAIDs during follow-up (aHR 0.55, 95% CI 0.37–0.84). A dose–response relationship existed in NSAID cumulative days. The findings demonstrate that NSAID use reduces second cancer risk in a dose-dependent manner in patients with primary breast cancer.

Fertility Age Couples Motivation On Cervical Cancer Early Detection

Cervical cancer is most often attacking women. After breast cancer, cervical cancer becomes second cancer infecting women. (WHO, 2014). This research aims to get the results from the fertility age couples' motivation on cervical cancer early detection.The preparation of a scoping review adapted the Arksey O'Malley framework consisted of 5 stages: research questions with the PEOs framework (Population, Exposure, and Outcomes), searching literature using relevant databases. The 12 articles used to consist of 3 themes, namely sexual and reproductive health problems, sexual health problems, and sexual and reproductive health.

Lifetime Attributable Risk Estimates of Secondary Cancer after External Radiotherapy among Colorectal Cancer Survivors in Saudi Arabia

Radiation-induced second cancer is one of the crucial late side effects of radiotherapy treatment of first cancer. Although the second cancer induction mechanism is not well understood yet, many factors are related to its occurrences, such as age at exposure, dose to the organ and surrounding tissues, treatment modalities, and family history of cancer. This study aims to provide long-term estimates of second cancer incidence amongst colon cancer survivors in Saudi Arabia. The lifetime attributable risk (LAR) after radiation treatment of the colon cancer was determined, between the age at exposure and up to 95 years, in a single-institution cohort of male and female cancer survivors whose age at treatment was in the range 43 to 85 years. Risk estimates varied significantly with age at exposure, gender, and organ dose.